Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Summary

This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in the body (advanced) and have come back (relapsed) or do not respond to treatment (refractory). Olaparib is an inhibitor of PARP, an enzyme that helps repair DNA when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

Conditions

• Advanced Malignant Solid Neoplasm
• Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
• Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
• Low Grade Glioma
• Malignant Glioma
• Recurrent Childhood Central Nervous System Neoplasm
• Recurrent Childhood Ependymoma
• Recurrent Childhood Malignant Germ Cell Tumor
• Recurrent Childhood Non-Hodgkin Lymphoma
• Recurrent Childhood Rhabdomyosarcoma
• Recurrent Childhood Soft Tissue Sarcoma
• Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
• Recurrent Glioma
• Recurrent Hepatoblastoma
• Recurrent Langerhans Cell Histiocytosis
• Recurrent Malignant Solid Neoplasm
• Recurrent Medulloblastoma
• Recurrent Neuroblastoma
• Recurrent Osteosarcoma
• Refractory Childhood Malignant Germ Cell Tumor
• Refractory Ependymoma
• Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
• Refractory Glioma
• Refractory Hepatoblastoma
• Refractory Langerhans Cell Histiocytosis
• Refractory Malignant Glioma
• Refractory Malignant Solid Neoplasm
• Refractory Medulloblastoma
• Refractory Neuroblastoma
• Refractory Non-Hodgkin Lymphoma
• Refractory Osteosarcoma
• Refractory Primary Central Nervous System Neoplasm
• Refractory Rhabdomyosarcoma
• Refractory Soft Tissue Sarcoma
• Rhabdoid Tumor
• Wilms Tumor

Interventions

DRUG

Olaparib

Given PO

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Julia Glade-Bender · Children's Oncology Group

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

12 Months

Max Age

21 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-09-14

Primary Completion

2023-03-31

Completion

2024-06-30

FDA Drug

Yes

Countries

• United States
• Puerto Rico

Study Locations